Losarta 12.5

/ CTS

Heart failure in adults: The starting dosage is usually 12.5 mg in one dose per day. Increase the daily dosage gradually until reaching the desirable maximal effect, as determined by the doctor. The maximal dosage is 150 mg per day.
See prescribing information for full details.

Treatment of hypertension.Treatment of heart failure (NYHA ll and lll) usually in addition to diuretics and/or digitalis, if use of an ACE inhibitor is not appropriate. Switching patients with heart failure who are stable on an ACE inhibitor is not recommended. To delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.To reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. The benefit of losartan on the primary composite endpoint was largely driven by reduction in the risk of stroke.

Known hypersensitivity to any component of the product. Pregnancy. Lctation.

See prescribing information for full details.

See prescribing information for full details.

See prescribing information for full details.

Although there is no experience with the use in pregnant women, animal studies have demonstrated fetal and neonatal injury and death, the mechanism of which is believed to be pharmacologically mediated through effects on the renin-angiotensin system. In humans, fetal renal perfusion, which is dependent upon the development of the renin-angiotensin system, begins in the second trimester, thus, risk to the fetus increases if treatment is administered during the second or third trimesters of pregnancy. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death in the developing fetus. When pregnancy is detected, treatment should be discontinued as soon as possible. It is not known whether losartan is excreted in human milk. However, significant levels of losartan and the active metabolite were shown in rat milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.